Literature DB >> 8096945

Leukotriene E4 and granulocytic infiltration into asthmatic airways.

L A Laitinen1, A Laitinen, T Haahtela, V Vilkka, B W Spur, T H Lee.   

Abstract

Sulphidopeptide leukotrienes are potent bronchoconstrictors and increase bronchial hyperreactivity, one of the hallmarks of asthma. We have demonstrated that leukotriene LTE4, the most stable of the sulphidopeptide leukotrienes, elicited an increase in the numbers of eosinophils and neutrophils in the lamina propria of the airway mucosa 4 h after inhalation in 4 asthmatic subjects. The numbers of eosinophils were, on average, 10-fold greater than those of neutrophils. There was no significant change in numbers of lymphocytes, plasma cells, mast cells, or macrophages. Since LTE4 recruits granulocytes, the potential of antisulphidopeptide leukotriene drugs as anti-inflammatory and "steroid-sparing" agents should be tested.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8096945     DOI: 10.1016/0140-6736(93)91073-u

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  91 in total

Review 1.  Leukotriene receptors.

Authors:  S E Dahlén
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Antileukotrienes and laboratory models of asthma.

Authors:  S C Lazarus
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 3.  Biochemistry and physiology of the leukotrienes.

Authors:  N C Barnes; L J Smith
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 4.  Update in internal medicine.

Authors:  F López-Jiménez; M Brito; Y W Aude; P Scheinberg; M Kaplan; D A Dixon; N Schneiderman; J F Trejo; L H López-Salazar; E J Ramírez-Barba; R Kalil; C Ortiz; J Goyos; A Buenaño; S Kottiech; G A Lamas
Journal:  Arch Med Res       Date:  2000 Jul-Aug       Impact factor: 2.235

5.  Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast.

Authors:  A P Sampson; S Siddiqui; D Buchanan; P H Howarth; S T Holgate; J W Holloway; I Sayers
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 6.  Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma.

Authors:  C J Dunn; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 7.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

Review 9.  Leukotriene receptors as potential therapeutic targets.

Authors:  Takehiko Yokomizo; Motonao Nakamura; Takao Shimizu
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

10.  Effect of a 5-lipoxygenase inhibitor and leukotriene antagonist (PF 5901) on antigen-induced airway responses in neonatally immunized rabbits.

Authors:  C M Herd; D Donigi-Gale; T S Shoupe; D A Burroughs; M Yeadon; C P Page
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.